Celator Pharma Cmn (CPXX) 30.24 $CPXX Hercules Announces

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Celator Pharma Cmn (CPXX) 30.24 $CPXX

Hercules Announces Strong Second Quarter Financial Results with $0.32 NII per Share and a $0.31 Quarterly Dividend
BusinessWire - Thu Aug 04, 3:05PM CDT
--Q2 2016 Financial Highlights
TPIC: 19.79 (-0.10), HTGC: 13.69 (+0.03), NUAN: 14.60 (+0.02), PFE: 34.68 (-0.12), BIND: 0.78 (-0.09), RLOC: 4.60 (unch), CPXX: 30.24 (unch), HTGY: 25.84 (unch), HTGZ: 25.59 (+0.09), GCI: 11.77 (-0.16), HTGX: 26.14 (+0.12), JAZZ: 123.31 (-0.52), ANAC: 99.06 (-0.14), EACQ: 9.73 (-0.15)

Drugs - Generic Stocks Technical Data - Allergan, Mylan, Horizon Pharma, and Celator Pharma
PR Newswire - Fri Jun 17, 7:00AM CDT
On Thursday, June 16, 2016, the NASDAQ Composite ended the trading session at 4,844.92, up 0.21%; the Dow Jones Industrial Average advanced 0.53% to finish at 17,733.10; and the S&P 500 closed at 2,077.99, up 0.31%. The gains were broad based as seven out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Allergan PLC (NYSE: AGN), Mylan N.V. (NASDAQ: MYL), Horizon Pharma PLC (NASDAQ: HZNP), and Celator Pharmaceuticals Inc. (NASDAQ: CPXX). Learn more about these stocks by accessing their free trade alerts at:
CPXX: 30.24 (unch), AGN: 237.76 (+3.22), HZNP: 18.62 (-0.18), MYL: 41.92 (-0.44)

Celator Pharmaceuticals® Announces Positive Results in Patients with FLT3 Mutation from the Phase 3 Trial in High-Risk Acute Myeloid Leukemia
PR Newswire - Tue Jun 14, 6:00AM CDT
Celator Pharmaceuticals, Inc. (Nasdaq: CPXX) today announced positive response rate results in AML patients with FLT3 (FMS-like tyrosine kinase-3) mutation were presented at the European Hematology Association (EHA) 21st Annual Congress. The results are from the Company's Phase 3 trial of VYXEOS(TM) (cytarabine: daunorubicin) Liposome for Injection (also known as CPX-351) in patients with high-risk (secondary) acute myeloid leukemia (AML).
CPXX: 30.24 (unch)

SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Celator Pharmaceuticals, Inc. - CPXX
ACCESSWIRE - Wed Jun 08, 5:36PM CDT
BALA CYNWYD, PA / ACCESSWIRE / June 8, 2016 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Celator Pharmaceuticals, Inc. ("Celator" or "the Company" (Nasdaq: CPXX) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Jazz Pharmaceuticals plc, ("Jazz".
CPXX: 30.24 (unch), JAZZ: 123.31 (-0.52)

Celator Pharmaceuticals® Presented Phase 3 Trial Results in Patients with High-Risk Acute Myeloid Leukemia Demonstrating VYXEOS(TM) (CPX-351) Significantly Improved Overall Survival
PR Newswire - Mon Jun 06, 6:00AM CDT
Celator Pharmaceuticals, Inc. (Nasdaq: CPXX) today announced results from its Phase 3 trial of VYXEOS(TM) (cytarabine: daunorubicin) Liposome for Injection (also known as CPX-351) in patients with high-risk (secondary) acute myeloid leukemia (AML) were presented at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting. As previously reported, the trial met its primary endpoint demonstrating a statistically significant improvement in overall survival. The Phase 3 trial compared to the standard of care regimen of cytarabine and daunorubicin known as 7+3.
CPXX: 30.24 (unch)

Celator Pharmaceuticals, Inc. Acquisition May Not Be in the Best Interests of CPXX Shareholders
PR Newswire - Fri Jun 03, 5:21PM CDT
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Celator Pharmaceuticals, Inc. ("CPXX" or the "Company" in connection with the proposed acquisition of the Company by Jazz Pharmaceuticals plc ("Jazz". On May 31, 2016, the Company announced it had reached a definitive agreement for Jazz to acquire all outstanding shares of CPXX pursuant to a tender offer for $30.25 in cash for each share of Company common stock.
CPXX: 30.24 (unch), JAZZ: 123.31 (-0.52)

CELATOR PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Sale to Jazz Pharmaceuticals plc
BusinessWire - Thu Jun 02, 12:22PM CDT
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Celator Pharmaceuticals, Inc. ("Celator" (NASDAQ: CPXX) concerning the sale to Jazz Pharmaceuticals plc. Under the terms of the agreement, Celator shareholders will only receive $30.25 in cash for each share owned.
CPXX: 30.24 (unch), JAZZ: 123.31 (-0.52)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

NSF Backs New Space Projects: Cooling & Drug Delivery

Updated Category News Views 2

You know, every time we think we're at the edge of current science, space reminds us how little we actually know. From the International Space Station up there in low Earth orbit, fresh experiments are kicking off to change what we understand about electronics cooling and drug delivery. It's a classic scenario of reaching for the stars to help us out back here on Earth....

Continue Reading
Aviator Nation Teams with NFL for 2026 Collection Launch

Updated Category News Views 6

In a move blending sports with a dash of retro flair, Aviator Nation's dropping its first NFL-licensed collection. They’re looking to serve up a blend of vintage vibes and team spirit. Aviator Nation's New Venture Launching their collection on September 24th, 2026, Aviator Nation takes a dive deeper into sports licensing, after scoring a touchdown (literally!) with an...

Continue Reading
Clarius Named in TIME's Top HealthTech 2026 Again

Updated Category News Views 6

When a company gets the nod from TIME two years in a row, you know they’re not just tinkering with gadgets—they’re changing the game. Clarius Mobile Health, with its cutting-edge wireless ultrasound tech, has cemented its place in TIME's World's Top HealthTech Companies of 2026. Last I checked, repeating this kind of recognition never comes easy in such a fiercely...

Continue Reading
Brands Must Choose: Cost or Value Leadership?

Updated Category News Views 2

Navigating the Business Jungle: Strategic Choices Unveiled If you've ever found yourself tangled in a web of corporate doublespeak, then you'll nod along with this: all those lofty brand management strategies often boil down to a fight over dollars or dizzying customer satisfaction. What's the winning play? According to Info-Tech Research Group, it's about firmly standing...

Continue Reading
Retirement Security Faces Global Headwinds in 2026

Updated Category News Views 10

Grappling with an Uncertain Retirement Future Welcome to the 2026 Global Retirement Index (GRI), where it seems we're all being told to brace for a rough retirement ride. This year's results, crafted by Natixis Investment Managers and their pals at CoreData Research, spotlight just how shaky the ground has gotten. The core troublemakers? Aging populations, whopping public...

Continue Reading
Microplastics Webinar: Navigating Complex Regulations

Updated Category News Views 2

Buckle up, folks. The plastics debate is where regulatory battles and environmental concerns collide, and big changes are on the horizon. Let's talk about Bergeson & Campbell's latest shindig: "Plastics and Policy: Microplastics, EPR, and Other Emerging Trends"—a free-to-join webinar aiming to lift the lid on what's brewing beneath the surface of regulatory waters. The...

Continue Reading
Lincoln Educational Services Faces Securities Fraud Suit

Updated Category News Views 2

A Storm Brews Over Lincoln Educational Services You know, there's nothing quite like the stink of a good mess in the markets, and Lincoln Educational Services Corporation has found itself knee-deep in one. The buzz is all about some securities fraud allegations that could rope in a bunch of investors who got the short end of the stick. It’s lawsuits like these that make...

Continue Reading
Starr Conspiracy Unveils AI Tool for B2B Tech Firms

Updated Category News Views 2

AI-Driven Insight in Minutes: A Game Changer for B2B Hold onto your hats, because The Starr Conspiracy just lit a fire in the B2B tech world with its latest offering—Battle Card Builder. This free tool cranks out competitive intelligence in no time, literally about four minutes. Geared specifically for B2B tech marketing and sales teams, it combines decades of know-how...

Continue Reading
Amy Wilson Joins ITSA Board: A New Era for UBI?

Updated Category News Views 6

An Unexpected Turn in the UBI Movement In a world where tech and economic security must dance together, minding the steps is crucial. And this time, Amy Wilson's got her dancing shoes on. On September 24, 2026, the Income To Support All (ITSA) Foundation made some waves by adding Wilson to its board of directors, a move showing they're more serious than ever about...

Continue Reading
illycaffè's B Corp™ Recertification Reflects Bold Commitment

Updated Category News Views 2

illycaffè Hits Milestone with B Corp™ Recertification In an era where corporate responsibility isn't just fodder for feel-good presentations, illycaffè has proven it’s not just paying lip service to the idea. The Italian coffee titan has secured its B Corp™ recertification under snazzier, sharper V2 standards. This isn't just a shiny sticker to slap on marketing...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding the Growing Investor Sentiment for OPCH

Updated Category News Views 220

Growing Interest in Option Care Health Inc Option Care Health Inc (NYSE: OPCH) has experienced a notable rise in its short interest, as recently reported data shows an increase of 19.11%. This uptick indicates that the total number of shares sold short has reached approximately 5.55 million, making up about 5.36% of all available shares for trading. What Does Short...

Continue Reading
Revive Real Estate Transforms Santa's Home into a Holiday Haven

Updated Category News Views 165

Santa's Home Transformed for the Holidays Santa and Mrs. Claus are embracing the festive season with an exciting renovation of their cherished home. After centuries filled with joy and holiday spirit, their iconic cabin has undergone a magical transformation thanks to the talented team at Revive Real Estate. The design team, which could easily be compared to elves, has...

Continue Reading
Understanding the Legal Implications for Flywire Investors

Updated Category News Views 112

Repercussions of the Flywire Securities Class Action The ongoing securities fraud class action against Flywire Corporation (NASDAQ: FLYW) is a significant development for its investors. Legal wrangling signifies a serious concern regarding the company's transparency and credibility. Investors who have recently transacted with Flywire need to pay attention to these...

Continue Reading
Grech RV Unveils Luxury Experience Showcasing Innovative Designs

Updated Category News Views 87

Unveiling a New Era of Luxury RV Experiences Grech RV is set to redefine the world of luxury recreational vehicles with an extraordinary event designed to immerse attendees in the brand's innovative spirit. The anticipated event, titled Grech RV Experience, promises to captivate both current RV owners and future enthusiasts alike. Emphasizing high-quality craftsmanship,...

Continue Reading
Global Net Lease's Positive Financial Trends for 2024

Updated Category News Views 108

Global Net Lease Reports Financial Success in 2024 Global Net Lease, Inc. (NYSE: GNL), a real estate investment trust specializing in net lease properties, announced impressive financial and operating results for the year ending December 31, 2024. The company has made significant strides in managing its portfolio and enhancing financial metrics, showcasing a commitment to...

Continue Reading